AU2017204973A1 - Novel fluorinated quinazoline derivatives as EGFR inhibitors - Google Patents
Novel fluorinated quinazoline derivatives as EGFR inhibitors Download PDFInfo
- Publication number
- AU2017204973A1 AU2017204973A1 AU2017204973A AU2017204973A AU2017204973A1 AU 2017204973 A1 AU2017204973 A1 AU 2017204973A1 AU 2017204973 A AU2017204973 A AU 2017204973A AU 2017204973 A AU2017204973 A AU 2017204973A AU 2017204973 A1 AU2017204973 A1 AU 2017204973A1
- Authority
- AU
- Australia
- Prior art keywords
- difluoromethoxy
- compound
- enamide
- ethoxy
- anilino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- JURZLIHWMFGBNN-UHFFFAOYSA-N COc1cc2ncnc(Nc(ccc(Cl)c3Cl)c3F)c2cc1[N+](O)=O Chemical compound COc1cc2ncnc(Nc(ccc(Cl)c3Cl)c3F)c2cc1[N+](O)=O JURZLIHWMFGBNN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275376P | 2016-01-06 | 2016-01-06 | |
| US62/275,376 | 2016-01-06 | ||
| PCT/CA2017/050015 WO2017117680A1 (en) | 2016-01-06 | 2017-01-06 | Novel fluorinated quinazoline derivatives as egfr inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017204973A1 true AU2017204973A1 (en) | 2018-07-12 |
Family
ID=59273095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017204973A Abandoned AU2017204973A1 (en) | 2016-01-06 | 2017-01-06 | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190016689A1 (enExample) |
| EP (1) | EP3400216A4 (enExample) |
| JP (1) | JP2019504830A (enExample) |
| CN (1) | CN108779079A (enExample) |
| AU (1) | AU2017204973A1 (enExample) |
| CA (1) | CA3008312A1 (enExample) |
| WO (1) | WO2017117680A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240017986A (ko) * | 2017-09-26 | 2024-02-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 조성물 및 방법 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US12523663B2 (en) | 2019-06-04 | 2026-01-13 | Inserm (Institut National De La Santé Et De La Rescherche Médicale) | Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| MX2022006691A (es) * | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111548314B (zh) * | 2020-05-22 | 2021-09-03 | 上海万巷制药有限公司 | 一种n-(3-氯-4-氟苯基)-7-氟-6-硝基-4-喹唑啉胺的生产方法 |
| MX2022015703A (es) | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| CN113264888A (zh) * | 2021-03-04 | 2021-08-17 | 江苏康可得生物技术股份有限公司 | 酪氨酸激酶抑制剂及其药物应用 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| CA3233057A1 (en) | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
| WO2023128350A1 (ko) * | 2021-12-30 | 2023-07-06 | 주식회사 비투에스바이오 | 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| CN119241448A (zh) * | 2024-08-16 | 2025-01-03 | 安润医药科技（苏州）有限公司 | 一种酪氨酸激酶抑制剂的可药用盐、晶体、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110958T1 (hr) * | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| CN102731485B (zh) * | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| JP2014532063A (ja) * | 2011-10-12 | 2014-12-04 | テリジェン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ | キナーゼ阻害剤としてのキナゾリン誘導体およびその使用方法 |
| WO2013166952A1 (en) * | 2012-05-07 | 2013-11-14 | Teligene Ltd | Substituted aminoquinazolines useful as kinases inhibitors |
| CN104910140A (zh) * | 2014-03-14 | 2015-09-16 | 齐鲁制药有限公司 | 喹唑啉类化合物、其制备方法及应用 |
| WO2016023217A1 (zh) * | 2014-08-15 | 2016-02-18 | 安润医药科技（苏州）有限公司 | 喹唑啉衍生物、其制备方法、药物组合物和应用 |
-
2017
- 2017-01-06 CA CA3008312A patent/CA3008312A1/en not_active Abandoned
- 2017-01-06 JP JP2018535293A patent/JP2019504830A/ja not_active Withdrawn
- 2017-01-06 EP EP17735790.2A patent/EP3400216A4/en not_active Withdrawn
- 2017-01-06 WO PCT/CA2017/050015 patent/WO2017117680A1/en not_active Ceased
- 2017-01-06 CN CN201780015324.4A patent/CN108779079A/zh active Pending
- 2017-01-06 US US16/066,574 patent/US20190016689A1/en not_active Abandoned
- 2017-01-06 AU AU2017204973A patent/AU2017204973A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3400216A1 (en) | 2018-11-14 |
| CA3008312A1 (en) | 2017-07-13 |
| CN108779079A (zh) | 2018-11-09 |
| JP2019504830A (ja) | 2019-02-21 |
| EP3400216A4 (en) | 2019-08-14 |
| WO2017117680A1 (en) | 2017-07-13 |
| US20190016689A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3400216A1 (en) | Novel fluorinated quinazoline derivatives as egfr inhibitors | |
| US20180050993A1 (en) | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers | |
| AU2015225745B2 (en) | Heterocyclic compounds | |
| US10696670B2 (en) | Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins | |
| JP6114820B2 (ja) | プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用 | |
| ES2738573T3 (es) | Sal de compuesto heterocíclico que contiene nitrógeno o cristal del mismo, composición farmacéutica e inhibidor de FLT3 | |
| US10369145B2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
| BR112016003247B1 (pt) | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso | |
| CA2881045A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b. | |
| AU2017226005A1 (en) | Inhibitors of WDR5 protein-protein binding | |
| CN108727382B (zh) | 作为btk抑制剂的杂环化合物及其应用 | |
| AU2015274285C1 (en) | Pyrimidine compounds and methods using the same | |
| WO2020181386A1 (en) | Fluorinated benzo[f]benzimidazol-4-9-dione ium derivatives and pharmaceutical compositions thereof and their use as survivin suppressants | |
| US20220041559A1 (en) | Benzo-and pyrido-pyrazoles as protein kinase inhibitors | |
| WO2019071351A1 (en) | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS | |
| WO2017140269A1 (zh) | 一类取代的氨基六元氮杂环类化合物及其制备和用途 | |
| WO2018081211A1 (en) | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide | |
| CN115996911A (zh) | 具有p2x4受体拮抗活性的取代的n-苯乙酰胺 | |
| Khan et al. | Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates | |
| CN116987073B (zh) | 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用 | |
| HK40085155A (en) | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |